US-HEALTH-VIRUS

In this photo illustration a Gilead logo is displayed on a smartphone next to a screen showing a coronavirus graphic on March 25, 2020 in Arlington, Virginia. - Gilead announced on March 25, 2020 that it has submitted a request to the Food and Drug Administration to rescind the exclusive marketing rights it had secured for remdesivir, an antiviral drug that shows promise in treating Covid-19, the disease caused by the new coronavirus. (Photo by Olivier DOULIERY / AFP) (Photo by OLIVIER DOULIERY/AFP via Getty Images)
In this photo illustration a Gilead logo is displayed on a smartphone next to a screen showing a coronavirus graphic on March 25, 2020 in Arlington, Virginia. - Gilead announced on March 25, 2020 that it has submitted a request to the Food and Drug Administration to rescind the exclusive marketing rights it had secured for remdesivir, an antiviral drug that shows promise in treating Covid-19, the disease caused by the new coronavirus. (Photo by Olivier DOULIERY / AFP) (Photo by OLIVIER DOULIERY/AFP via Getty Images)
US-HEALTH-VIRUS
PURCHASE A LICENSE
How can I use this image?
$499.00
USD

DETAILS

Restrictions:
Contact your local office for all commercial or promotional uses. Full editorial rights UK, US, Ireland, Italy, Spain, Canada (not Quebec). Restricted editorial rights elsewhere, please call local office.
Credit:
OLIVIER DOULIERY / Contributor
Editorial #:
1208237136
Collection:
AFP
Date created:
March 25, 2020
License type:
Rights-managed
Release info:
Not released. More information
Source:
AFP
Barcode:
AFP
Object name:
AFP_1Q67SP
Max file size:
4000 x 2507 px (13.33 x 8.36 in) - 300 dpi - 2 MB